In many cancers, including skin cancer, PD-L1 expression has been positively associated with response to immunotherapy; therefore, treatment strategies are often guided by immunohistochemistry (IHC)-based diagnostic tests assessing the expression of PD-L1 [266]. This evidence concerns the gene CD274 and cancer.